Helix BioPharma Corp
Open
$2.02
Prev. Close
$1.96
High
$2.04
Low
$2.02
Market Snapshot
$50.9M
-0.08
7
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario and currently employs 7 full-time employees. The firm is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
emptyResult
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario and currently employs 7 full-time employees. The firm is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
Recently from Cashu
Helix BioPharma Corp. Advances Cancer Treatment with Innovative Oncology Therapies
Helix BioPharma Advances Oncology Solutions Through Innovative Therapies Helix BioPharma Corp., a clinical-stage oncology company, is making significant strides in the development of novel therapies f…
Helix BioPharma Corp. Advances Cancer Therapies with Recent Financial Filing and Pipeline Updates
Helix BioPharma Advances Innovative Cancer Therapies with New Financial Filing Helix BioPharma Corp., a clinical-stage oncology company based in Canada, has recently filed its unaudited interim financ…